Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
6.75
-0.30 (-4.26%)
Jun 24, 2025, 4:00 PM - Market closed

Actuate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
8.726.483.273.82
Research & Development
15.0418.6821.7116.39
Operating Expenses
23.7525.1624.9720.21
Operating Income
-23.75-25.16-24.97-20.21
Interest Expense
-0.02-0.02-0.04-0.02
Interest & Investment Income
0.260.220.350.03
Other Non Operating Income (Expenses)
-0.05-0.08-0.080.04
EBT Excluding Unusual Items
-23.56-25.04-24.74-20.16
Other Unusual Items
-1.75-2.25--
Pretax Income
-25.31-27.29-24.74-20.16
Net Income
-25.31-27.29-24.74-20.16
Net Income to Common
-25.31-27.29-24.74-20.16
Shares Outstanding (Basic)
13811
Shares Outstanding (Diluted)
13811
Shares Change (YoY)
766.91%483.48%18.54%-
EPS (Basic)
-1.97-3.26-17.24-16.65
EPS (Diluted)
-1.97-3.26-17.24-16.65
EBIT
-23.75-25.16-24.97-20.21
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q